Skip to main content
Premium Trial:

Request an Annual Quote

But This Uses Cool Toys

The Boston Globe takes a look at Knome, the consumer genomic company that sequences its customers' genomes while rounding up the challenges facing the field -- those cease-and-desist letters and the debate over medical relevance. The writer, Scott Kirsner, asks Raju Kucherlapati and David Altshuler if they'd get their genomes sequenced. Kucherlapati already had his looked at by Navigenics -- it confirmed problems he thought would be there -- and Altshuler, who turned that test down, says that a good family history also does the trick.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.